The news: Pharma promotions and financial ties to physicians may be associated with less appropriate prescribing, higher prescription volumes, and increased drug costs, according to a new Cochrane Library study. Researchers reviewed 93 studies, mostly US-based, examining the relationship between pharma companies and physician prescribing.

The study unveiled three key ways in which pharma company marketing has influenced doctors’ prescribing behaviors:

• Advertising and education: Exposure to pharma advertising, sales reps, and product information may increase inappropriate prescribing and drug costs (such as prescribing a less suitable or more expensive drug when a safer or cheaper alternative is available), while probably increasing prescription volumes.
• Gifts and payments: Physicians who received transfers of value, such as sponsored meals, were more likely to prescribe inappropriate treatments and write more prescriptions.
• Greater exposure, greater influence: Physicians with more interactions with pharma companies tended to prescribe less appropriate medications and write more prescriptions.

Conversely, hospital and healthcare organization policies that limit industry gifts, payments, and promotional contact probably improve prescribing appropriateness and may reduce prescription volumes.

Why it matters: The findings suggest pharma marketing is influencing prescribing decisions in drugmakers’ favor, raising concerns about whether physicians can maintain independent clinical judgment when personal rapport, gifts, and other incentives may subtly shape treatment choices.

At the same time, some of these historically influential marketing tactics may become harder to sustain. Access to drug sales reps has declined or become more selective as physicians have less time for traditional sales interactions, institutional conflict-of-interest policies tighten, and doctors increasingly favor independent digital research.

Implications for pharma marketers: Federal agencies and oversight bodies have long pushed for transparency around pharma-physician conflicts of interest, but changes in pharma B2B marketing have largely been limited to reduced rep access and curbs on certain lavish promotions, such as expensive trips. Still, growing pressure for transparency and clinical objectivity could eventually intensify healthcare organizations’ scrutiny of industry-sponsored education, sales interactions, and other promotions.

Pharma marketers will need to make limited interactions more valuable by better understanding doctors’ patient populations and preferences for engaging with drug and treatment content. AI can help pharma marketers tailor messaging to physicians’ clinical needs and interests, while analytics tools can provide pharma marketers with behind-the-scenes value that doesn’t take up physicians’ time by tracking physicians’ digital engagement, allowing for real-time campaign adjustments.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.